New Kinase Target STK40 Cracks Open Liver Cancer Immune Resistance
A CRISPR screen reveals STK40 suppresses anti-tumor immunity in liver cancer — blocking it supercharges immunotherapy response.
Summary
Researchers used CRISPR screening to identify STK40, a kinase that helps liver cancer cells hide from the immune system. When STK40 is blocked, tumors become vulnerable to immune attack in two ways: cancer cells regain sensitivity to T cell killing, and more immune-activating dendritic cells are recruited to the tumor. Combining an STK40-blocking therapy with a standard PD-1 checkpoint inhibitor produced strong anti-tumor responses in multiple cancer models. This discovery offers a new target for patients with hepatocellular carcinoma — a liver cancer that frequently resists existing immunotherapies — and potentially for other cancer types as well.
Detailed Summary
Hepatocellular carcinoma (HCC) is one of the deadliest cancers worldwide, and despite the promise of immunotherapy, most patients do not respond. Understanding the molecular mechanisms that let liver tumors evade immune attack is essential for developing better treatments.
Using in vivo CRISPR-Cas9 screens, researchers at Shanghai Jiao Tong University and collaborating institutions identified serine/threonine kinase 40 (STK40) as a previously unknown driver of immune evasion in HCC. Deleting Stk40 in hepatocytes completely blocked tumor formation in mouse models, and combining STK40 loss with PD-1 blockade drove significant tumor regression.
The mechanism operates on two fronts. First, STK40 normally acts as a scaffold for the COP1 ubiquitin ligase, which targets interferon gamma receptor 1 (IFNGR1) for degradation. By eliminating STK40, IFNGR1 is stabilized on tumor cells, restoring their sensitivity to T cell–mediated killing. Second, Stk40 loss triggers autonomous secretion of GM-CSF by tumor cells, recruiting and activating conventional type 1 dendritic cells. These dendritic cells enhance antigen cross-presentation, amplifying CD8+ T cell responses against the tumor.
Pharmacologically, the team delivered STK40-targeting siRNA via lipid nanoparticles (LNP-siRNA) and combined this with PD-1 blockade. This combination produced potent anti-tumor responses across multiple cancer types in preclinical models, suggesting the approach is not limited to HCC.
Caveats include that all findings are preclinical and the summary is based on the abstract alone. Translation to human patients will require clinical trials to confirm safety and efficacy. Nevertheless, STK40 represents a compelling dual-action therapeutic target — simultaneously sensitizing tumor cells to cytotoxic T cells and reshaping the immune microenvironment to favor anti-tumor activity.
Key Findings
- STK40 promotes immune evasion in liver cancer by degrading IFNGR1 via COP1 ubiquitin ligase scaffolding.
- Stk40 deletion stabilizes IFNGR1 on tumor cells, restoring sensitivity to T cell killing.
- STK40 loss triggers GM-CSF secretion, boosting dendritic cell infiltration and CD8+ T cell activation.
- LNP-siRNA targeting STK40 combined with PD-1 blockade shows potent anti-tumor effects across cancer types.
- Hepatocyte-specific Stk40 deletion fully abolished tumorigenesis in HCC mouse models.
Methodology
The study used in vivo CRISPR-Cas9 screens to identify STK40, validated mechanistic findings in hydrodynamic plasmid-driven HCC mouse models, and tested pharmacological inhibition using LNP-delivered siRNA combined with anti-PD-1 therapy across multiple tumor models. Both genetic depletion and pharmacological targeting approaches were employed.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. All findings are preclinical; human clinical trials have not yet been conducted. The durability of responses and potential off-target effects of STK40 inhibition in normal tissues remain to be characterized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.